Accustem Sciences Inc. Overview
Industry: Biotechnology
Sector: Healthcare
Accustem Sciences Inc., a clinical stage diagnostics company, develops and commercializes products for the treatment and management of various cancers. Its primary product candidate is StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. The company was incorporated in 2021 and is headquartered in New York, New York. Accustem Sciences Inc., a clinical stage diagnostics company, develops and commercializes products for the treatment and management of various cancers. Its primary product candidate is StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients Read MoreAccustem Sciences Inc. is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.
Accustem Sciences Inc.
Score